TPO-RAs combining anti-CD 20 monoclonal antibody ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
63特発性血小板減少性紫斑病1

63. 特発性血小板減少性紫斑病


臨床試験数 : 391 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05718856
(ClinicalTrials.gov)
April 1, 202313/11/2022TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)A Multicenter, Randomized, Open-label StudyTo Compare The Efficacy And Safety Of TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in Persistent or Chronic Pediatric ITP Patients Who Failed or Relapse After Hormone TherapyPrimary Immune Thrombocytopenia (ITP)Drug: TPO-RAs;Drug: TPO-RAs combining anti-CD 20 monoclonal antibodyInstitute of Hematology & Blood Diseases HospitalBeijing Children's Hospital;Tianjin People's Hospital;The Second Affiliated Hospital of Kunming Medical University;Henan Cancer Hospital;Tianjin Medical University Second Hospital;The First Affiliated Hospital of Xiamen UniversityNot yet recruiting6 Years17 YearsAll166Phase 4China